Iovance Reports Durable Responses With Lifileucel in Early Soft Tissue Sarcoma Trial

By Public Technologies
  • Iovance Biotherapeutics will present lifileucel clinical results at the ESMO Congress in Madrid on October 23-27, 2026.
  • Final Phase 2 results showed deep, durable responses with lifileucel combined with pembrolizumab in previously untreated advanced melanoma.
  • The findings support the ongoing Phase 3 TILVANCE-301 trial evaluating lifileucel earlier in advanced melanoma treatment.
  • A pilot trial showed durable responses in previously treated undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma, supporting the ongoing SARATOGA registrational trial.
  • An indirect comparison suggested improved long-term overall survival with lifileucel versus standard treatments in anti-PD-1-resistant advanced melanoma.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190700PRIMZONEFULLFEED9847932) on October 19, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.